NAD+ Precursors (NMN/NR)
250 to 1,000 mg daily. Strong mechanistic case, limited human outcome data.
What it does
NAD+ is central to energy metabolism, DNA repair, and sirtuin signaling, and declines with age — a strong mechanistic case. Human outcomes data is still thin: small, short, biomarker-focused. Worth tracking as evidence develops.
NMN and NR are precursors converted to NAD+, the coenzyme for energy metabolism, DNA repair (PARP activity), and sirtuin signaling. NAD+ declines with age across tissues.
What the evidence shows
Overall evidence strength: Low certainty
Who it's for, who should skip
Experimental. Oral precursors are cheaper and more sustainable than IV infusions and at least as well-evidenced. Whether raising blood NAD+ changes health outcomes is the open question.
Running it
- Form
- oral
- Dose
- 250–1,000 mg · daily · morning common; timing not well-established
Access & cost
Available over the counter. Look for: third-party tested NMN or NR.
Last reviewed 27 August 2026.